Synapse Discovery Could Lead To New Treatments For Alzheimer's Disease

Synapse Discovery Could Lead To New Treatments For Alzheimer's Disease

Article
Brain & Nerve
Behavioral & Mental Health
+1
Contributed byMaulik P. Purohit MD MPHDec 04, 2015

A team of researchers led by UNSW Australia scientists has discovered how connections between brain cells are destroyed in the early stages of Alzheimer's disease -- work that opens up a new avenue for research on possible treatments for the degenerative brain condition.

"One of the first signs of Alzheimer's disease is the loss of synapses -- the structures that connect neurons in the brain," says study leader, Dr Vladimir Sytnyk, of the UNSW School of Biotechnology and Biomolecular Sciences.

"Synapses are required for all brain functions, and particularly for learning and forming memories. In Alzheimer's disease, this loss of synapses occurs very early on, when people still only have mild cognitive impairment, and long before the nerve cells themselves die.

"We have identified a new molecular mechanism which directly contributes to this synapse loss -- a discovery we hope could eventually lead to earlier diagnosis of the disease and new treatments."

The team studied a protein in the brain called neural cell adhesion molecule 2, or NCAM2 -- one of a family of molecules that physically connects the membranes of synapses and help stabilise these long lasting synaptic contacts between neurons.

The research is published in the journal Nature Communications.

Using post-mortem brain tissue from people with and without the condition, they discovered that synaptic NCAM2 levels in the part of the brain known as the hippocampus were low in those with Alzheimer's disease.

They also showed in mice studies and in the laboratory that NCAM2 was broken down by another protein called beta-amyloid, which is the main component of the plaques that build up in the brains of people with the disease.

"Our research shows the loss of synapses is linked to the loss of NCAM2 as a result of the toxic effects of beta-amyloid," says Dr Sytnyk.

"It opens up a new avenue for research on possible treatments that can prevent the destruction of NCAM2 in the brain."


The above post is a redistributed news release provided by University of New South Wales. Note: Materials may be edited for content and length. 

Disclaimer: DoveMed is not responsible for the adapted accuracy of news releases posted to DoveMed by contributing universities and institutions.

Primary Resource:

Leshchyns’ka, I., Liew, H. T., Shepherd, C., Halliday, G. M., Stevens, C. H., Ke, Y. D., ... & Sytnyk, V. (2015). A [beta]-dependent reduction of NCAM2-mediated synaptic adhesion contributes to synapse loss in Alzheimer/'s disease. Nature Communications6

Was this article helpful

On the Article

Maulik P. Purohit MD MPH picture
Approved by

Maulik P. Purohit MD MPH

Assistant Medical Director, Medical Editorial Board, DoveMed Team

0 Comments

Please log in to post a comment.

Related Articles

Test Your Knowledge

Asked by users

Related Centers

Loading

Related Specialties

Loading card

Related Physicians

Related Procedures

Related Resources

Join DoveHubs

and connect with fellow professionals

Related Directories

Who we are

At DoveMed, our utmost priority is your well-being. We are an online medical resource dedicated to providing you with accurate and up-to-date information on a wide range of medical topics. But we're more than just an information hub - we genuinely care about your health journey. That's why we offer a variety of products tailored for both healthcare consumers and professionals, because we believe in empowering everyone involved in the care process.
Our mission is to create a user-friendly healthcare technology portal that helps you make better decisions about your overall health and well-being. We understand that navigating the complexities of healthcare can be overwhelming, so we strive to be a reliable and compassionate companion on your path to wellness.
As an impartial and trusted online resource, we connect healthcare seekers, physicians, and hospitals in a marketplace that promotes a higher quality, easy-to-use healthcare experience. You can trust that our content is unbiased and impartial, as it is trusted by physicians, researchers, and university professors around the globe. Importantly, we are not influenced or owned by any pharmaceutical, medical, or media companies. At DoveMed, we are a group of passionate individuals who deeply care about improving health and wellness for people everywhere. Your well-being is at the heart of everything we do.

© 2023 DoveMed. All rights reserved. It is not the intention of DoveMed to provide specific medical advice. DoveMed urges its users to consult a qualified healthcare professional for diagnosis and answers to their personal medical questions. Always call 911 (or your local emergency number) if you have a medical emergency!